Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
// Francesca Pistollato 1 , Elan L. Ohayon 2 , Ann Lam 1,2 , Gillian R. Langley 3 , Thomas J. Novak 4 , David Pamies 5 , George Perry 6 , Eugenia Trushina 7 , Robin S.B. Williams 8 , Alex E. Roher 9,10 , Thomas Hartung 5 , Stevan Harnad 11 , Neal Barnard 1 , Martha Clare Morris 12 , Mei-Chun Lai 1 , Ryan Merkley 1 and P. Charukeshi Chandrasekera 1 1 Physicians Committee for Responsible Medicine, Washington, DC, USA 2 Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA 3 Research and Toxicology Department, Humane Society International, London, UK 4 Cellular Dynamics International, Madison, WI, USA 5 CAAT, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 6 College of Sciences, University of Texas at San Antonio, San Antonio, TX, USA 7 Department of Neurology, Mayo Clinic, Rochester, MN, USA 8 Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham, UK 9 Division of Clinical Education, Midwestern University, Glendale, AZ, USA 10 Division of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA 11 Department of Psychology, University of Quebec/Montreal, Montreal, Canada 12 Section of Nutrition and Nutritional Epidemiology, Department of Internal Medicine, Rush University, Chicago, IL, USA Correspondence to: Francesca Pistollato, email: // Keywords : Alzheimer disease, animal models, human methods, induced pluripotent stem cells, computational models, Gerotarget Received : September 29, 2015 Accepted : April 18, 2016 Published : May 04, 2016 Abstract Much of Alzheimer disease (AD) research has been traditionally based on the use of animals, which have been extensively applied in an effort to both improve our understanding of the pathophysiological mechanisms of the disease and to test novel therapeutic approaches. However, decades of such research have not effectively translated into substantial therapeutic success for human patients. Here we critically discuss these issues in order to determine how existing human-based methods can be applied to study AD pathology and develop novel therapeutics. These methods, which include patient-derived cells, computational analysis and models, together with large-scale epidemiological studies represent novel and exciting tools to enhance and forward AD research. In particular, these methods are helping advance AD research by contributing multifactorial and multidimensional perspectives, especially considering the crucial role played by lifestyle risk factors in the determination of AD risk. In addition to research techniques, we also consider related pitfalls and flaws in the current research funding system. Conversely, we identify encouraging new trends in research and government policy. In light of these new research directions, we provide recommendations regarding prioritization of research funding. The goal of this document is to stimulate scientific and public discussion on the need to explore new avenues in AD research, considering outcome and ethics as core principles to reliably judge traditional research efforts and eventually undertake new research strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“In particular, both Aβ and NFT are known to often appear early in time and, according to novel hypotheses, might actually not be considered as causative of AD but rather a result of AD pathology, which is often characterized by neuroinflammation as well as hypometabolism [43, 75, 124].”
BackgroundRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“Although advancing age is clearly considered the main risk factor for developing AD [21-23], nutritional factors [24], low levels of physical activity [25, 26], reduced cognitive stimulation [27], socioeconomic status and educational attainment [28-30] are all directly related to AD risk.”
BackgroundAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253 · cited 1×
“For example, iPSCs have been widely applied in AD research [49-53] and can be used to: (i) assess clinical candidate drugs on human brain cell types; (ii) conduct phenotypic screening of compounds that modulate or normalize disease phenotype; (iii) conduct target-based screening if candidate genes are identified; (iv)…”
MethodMIND diet slows cognitive decline with aging
Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Barnes, L. L., Bennett, D. A., & Aggarwal, N. T. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.04.011 · Cited by 1,115
Self-citationIncidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051
Sleep and Alzheimer disease pathology--a bidirectional relationship
Ju, Y.-E. S., Lucey, B. P., & Holtzman, D. M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.269 · Cited by 996 · cited 1×
“Furthermore, poor sleep quality [31-33] which is known to positively correlate to early Aβ deposition [34, 35], air pollution [36], smoking [37], intake of metals [38-40], pesticides and insecticides [41, 42] as well as metabolic-related dysfunctions [43, 44] have all been described as possible risk factors.”
BackgroundHuman iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Mertens, J., Paquola, A. C. M., Ku, M., Hatch, E., Böhnke, L., Ladjevardi, S., McGrath, S., Campbell, B., Lee, H., Herdy, J. R., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.09.001 · Cited by 765
Cited by
Brain-Gut-Microbiota Axis in Alzheimer’s Disease
Kowalski, K., & Mulak, A. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18087 · Cited by 826
“to a variety of biological, social and environmental factors including the gut microbiota has been suggested.(118) An interdisciplinary approach to that complex field of host-microbiota interactions should”
BackgroundOrganoid intelligence (OI): the new frontier in biocomputing and intelligence-in-a-dish
Smirnova, L., Caffo, B. S., Gracias, D. H., Huang, Q., Morales Pantoja, I. E., Tang, B., Zack, D. J., Berlinicke, C. A., Boyd, J. L., Harris, T. D., et al. (2023) · Frontiers in Science · doi:10.3389/fsci.2023.1017235 · Cited by 276
Self-citationPistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
Self-citationAge-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients
Mertens, J., Herdy, J. R., Traxler, L., Schafer, S. T., Schlachetzki, J. C. M., Böhnke, L., Reid, D. A., Lee, H., Zangwill, D., Fernandes, D. P., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.04.004 · Cited by 240
Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K., & Pistollato, F. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231157756 · Cited by 219
Self-citationGrøntvedt, G. R., Schröder, T. N., Sando, S. B., White, L., Bråthen, G., & Doeller, C. F. (2018) · Current Biology · doi:10.1016/j.cub.2018.04.080 · Cited by 91
Metadata
- Authors
- Pistollato, F., Ohayon, E. L., Lam, A., Langley, G. R., Novak, T. J., Pamies, D., Perry, G., Trushina, E., Williams, R. S. B., Roher, A. E., Hartung, T., Harnad, S., Barnard, N., Morris, M. C., Lai, M.-C., Merkley, R., & Chandrasekera, P. C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-05-04
- Volume
- 7
- Issue
- 26
- Pages
- 38999-39016
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2346245458
- Cited by
- 77
- References
- 29
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.